Stifel Nicolaus Raises Celcuity (NASDAQ:CELC) Price Target to $42.00

Celcuity (NASDAQ:CELC) had its price objective hoisted by Stifel Nicolaus from $39.00 to $42.00 in a report published on Monday morning, Benzinga reports. They currently have a buy rating on the stock.

Other equities research analysts also recently issued reports about the stock. Needham & Company LLC reiterated a buy rating and set a $23.00 price objective on shares of Celcuity in a research note on Thursday, August 15th. Leerink Partnrs raised Celcuity to a strong-buy rating in a research report on Monday, July 22nd. Lifesci Capital started coverage on Celcuity in a report on Monday, August 26th. They issued an outperform rating and a $27.00 price objective on the stock. HC Wainwright reaffirmed a buy rating and set a $27.00 target price on shares of Celcuity in a report on Thursday, August 15th. Finally, Leerink Partners started coverage on shares of Celcuity in a report on Monday, July 22nd. They issued an outperform rating and a $29.00 price target on the stock. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of Buy and a consensus target price of $29.17.

Celcuity Stock Performance

Shares of NASDAQ:CELC opened at $14.50 on Monday. The firm has a 50 day moving average of $15.63 and a 200 day moving average of $16.58. The company has a quick ratio of 14.95, a current ratio of 14.95 and a debt-to-equity ratio of 0.54. The company has a market capitalization of $508.96 million, a price-to-earnings ratio of -5.22 and a beta of 0.75. Celcuity has a 52 week low of $8.62 and a 52 week high of $22.19.

Celcuity (NASDAQ:CELC) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.09. During the same period in the prior year, the business earned ($0.66) earnings per share. On average, sell-side analysts predict that Celcuity will post -2.54 earnings per share for the current fiscal year.

Institutional Trading of Celcuity

Hedge funds have recently modified their holdings of the stock. Quest Partners LLC raised its position in Celcuity by 31.3% during the second quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock valued at $95,000 after acquiring an additional 1,379 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Celcuity during the 3rd quarter valued at approximately $119,000. BNP Paribas Financial Markets increased its holdings in shares of Celcuity by 78.5% during the 1st quarter. BNP Paribas Financial Markets now owns 8,937 shares of the company’s stock valued at $193,000 after purchasing an additional 3,930 shares in the last quarter. Commonwealth Equity Services LLC lifted its stake in shares of Celcuity by 9.9% in the 2nd quarter. Commonwealth Equity Services LLC now owns 16,624 shares of the company’s stock valued at $272,000 after purchasing an additional 1,500 shares during the period. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in Celcuity by 7.8% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 22,030 shares of the company’s stock worth $361,000 after buying an additional 1,600 shares in the last quarter. Hedge funds and other institutional investors own 63.33% of the company’s stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.